Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in 70 to 90% of patients when treatment includes all-trans retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most often is due to a severe and often catastrophic bleeding, often intracerebral in location, and remains a major cause of treatment failure. Thrombosis, either at diagnosis or during the course of treatment, may be unrecognized and reflects the complexity of the coagulopathy. The dual phenomenon of bleeding and thrombosis is attributable to at least three processes: disseminated intravascular coagulation; fibrinolysis (generated in part by expression of annexin-II on the APL cell surface); and direct proteolysis of several proteins including fibrinogen and von Willebrand factor. Both ATRA and arsenic trioxide are associated with rapid resolution of the coagulopathy. The use of heparin, once a mainstay of therapy for patients with APL, has been all but abandoned. Preliminary studies suggest no role for the routine use of antifibrinolytic agents. The most important therapeutic strategy is early institution of ATRA at the first suspicion of the diagnosis (without waiting for genetic confirmation) and aggressive blood product support during induction.
In the initial description of acute promyelocytic leukemia (APL) as a distinct subtype of acute myeloid leukemia (AML) in 1957, Hillestad 1 recognized the importance of a severe bleeding tendency. At the time, he attributed the bleeding diathesis to fibrinolysis and thrombocytopenia, and suggested that APL was the most malignant form of acute leukemia. This observation proved to be correct, as reports of patients with APL emerged during the ensuing 30 years, describing a high rate of early death (ED) frequently due to catastrophic hemorrhage. As individual institutions and cooperative groups began to address this specific subtype of AML, the prominent primary azurophilic granules became the characteristic morphologic finding (Fig. 1) , and the dominant clinical manifestation of the disease was indeed severe and life-threatening bleeding, which proved to be the major cause of early mortality in every report. Approximately 20 to 30% of patients died of hemorrhage, most often intracerebral in location, either at presentation or after the initiation of chemotherapy. [2] [3] [4] [5] [6] Deciphering the pathogenesis of the bleeding diathesis became a major focus of research because the outcome of patients with APL appeared to be more favorable compared with that of patients with other subtypes of AML, provided that patients survive the first several weeks after the diagnosis.
The vitamin A derivative all-trans retinoic acid (ATRA) has altered the prognosis of patients with APL dramatically when combined with anthracycline-based chemotherapy. This therapy has transformed the disease from the most fatal to the most curable subtype of AML in adults. Historically, in the pre-ATRA era, the disease-free survival rate was 30 to 40%. [2] [3] [4] [5] [6] However, with contemporary treatment strategies, depending on prognostic factors and risk classification, 70 to 95% of patients can be expected to be cured of their disease. Furthermore, the introduction of ATRA has provided the opportunity to investigate the coagulopathy associated with APL more thoroughly because both clinical bleeding and biochemical evidence of perturbed coagulation are corrected rapidly with ATRA.
CLINICAL BLEEDING AND COAGULATION ABNORMALITIES IN APL
Autopsies in three patients with APL in 1966 showed the dual phenomenon of both excessive visceral and serosal hemorrhages and thromboses. 7 Early after the initial descriptions of patients with APL, it was recognized that most patients have evidence of widespread bleeding in the skin, as well as visceral organs. [2] [3] [4] [5] [6] [7] [8] Historically, intracerebral hemorrhage (ICH) has been the major cause of ED even in patients with modest thrombocytopenia or minimal evidence of apparent perturbed coagulation by routine tests. For example, Fig. 2 shows a computerized tomography scan of the brain of a 49-year-old man with APL who presented with a 2-week history of malaise and easy bruising, with a white blood cell count of 57,400/mL, hemoglobin 7.4 g, platelets 14,000/mL, prothrombin time (PT) 22.8 seconds, partial thromboplastin time (PTT) 32.2 seconds, fibrinogen < 60 mg/dL, and D-dimer 4.0mg/mL, who died of an ICH within 24 hours of seeking medical attention at a large medical center.
Routine coagulation tests reveal prolongations in the PT and PTT, low fibrinogen levels, and elevation in the D-dimer and fibrin degradation products (FDPs) in most but not all patients with APL. 8 These observations suggested that the bleeding diathesis is due to disseminated intravascular coagulation (DIC). 9 However, these coagulation abnormalities are 10 In a contemporary series of patients with APL treated with ATRA, the early mortality rate is only 10%, However, 30 to 60% of EDs are still attributable to bleeding. [11] [12] [13] [14] (Table 1 ) In a retrospective study of 34 consecutive patients with APL, the most common hemostatic abnormality was a low fibrinogen level, which was present in 61% of patients. 15 Relatively late pulmonary bleeding attributable to diffuse alveolar hemorrhage also has been described. 16 As has been observed in earlier studies, the PTT was normal in almost all patients and the PT was prolonged in only 44% of patients. Importantly, severe bleeding did not correlate with abnormalities in hemostatic parameters, but rather correlated with elevation in the white blood cell count. A normal PT and PTT or only a minimally elevated PTT in some patients provides additional evidence that the bleeding in patients with APL is more complicated. Although bleeding is the most frequent manifestation of perturbed coagulation, thrombosis, either before or during treatment, may be unrecognized, and reflects the interaction of procoagulant, anticoagulant, and proteolytic forces.
THROMBOSIS IN APL
Thrombosis in patients with APL has been manifested as pulmonary emboli, and thrombi in the superior sagittal sinus, cardiac ventricle, and in the deep veins. 7, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Splenic infarction and acute myocardial infarction due to thrombosis have also been reported. 23, 26 In an observational cohort study of 379 patients with newly diagnosed acute leukemia performed between 1994 and 2003, thrombosis was the presenting manifestation in 13 patients (3.4%) in the entire cohort; 9.6% of the 31 patients had APL. 27 At 6 months from diagnosis, the cumulative incidence of thrombosis was 8.4% in patients with APL compared with 3.2% in non-APL patients. The risk of thrombosis has been correlated with an elevated white blood cell count, the bcr3 promyelocyte (PML) isoform subtype of PML-RAR (retinoic acid receptor) -a, the presence of fms-like tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutations, and expression of CD2 and CD15. 25 It may be difficult to determine if the thrombosis is caused by perturbations in the coagulation system because of the underlying disease or because of the imbalance in procoagulant and anticoagulant forces created by treatment with ATRA (discussed in the next section). Occasionally, patients may present or develop both hemorrhage and thrombosis, the latter sometimes resulting in organ infarction, either from the disease or its treatment. This combination reflects the double hazard of thrombophilia and bleeding that may be present in patients with APL (Fig. 3) .
PATHOGENESIS OF THE COAGULOPATHY IN APL
Consumptive Coagulopathy and Procoagulant Activity The common findings in the peripheral blood in most patients with APL are a prolonged PT and PTT, thrombocytopenia, hypofibrinogenemia, and elevation in the fibrin split products and D-dimer. 8 The evidence of consumptive coagulopathy includes elevations in markers of activation of coagulopathy, including fibrinopeptide A (FPA), thrombin-antithrombin complex (TAT), and prothrombin fragment 1 þ 2 ( Table 2) . [28] [29] [30] However, many patients do not have all or even some of these abnormalities apart from thrombocytopenia and still have significant risk of potentially fatal bleeding. The abnormalities in the routine clotting tests are not diagnostic of any one single process, but rather reflect a complicated interaction of several processes. 31, 32 Early death due to bleeding may be worse in patients with the microgranular variant (M3V) of APL, which frequently is associated with hyperleukocytosis. 33, 34 The M3V may also be associated with the presence of FLT3 ITD mutations. [35] [36] [37] In one study, FLT3 ITD mutations were associated with an elevated white blood cell count, increased peripheral blast count, and high lactate dehydrogenase levels, but not with a low fibrinogen level or the presence of DIC. 35 What role, if any, such mutations play in the coagulopathy of APL has not yet been determined.
At least two procoagulant mediators have been described in patients with APL. The first is cancer procoagulant (CP), a cysteine proteinase, which has been identified in leukemia cells from patients with a variety of subtypes of AML, but with the highest activity demonstrated in leukemic promyelocytes. 38 The level of CP is high at the time of diagnosis and low when remission is achieved. 39 However, it was demonstrated subsequently that the activity of PC may be attributable to tissue factor (TF), the second procoagulant mediator. 40 Expression of TF, which is the major activator of coagulation, is elevated in patients with APL. 41 Expression of TF may also be induced from endothelial cells by various inflammatory cytokines released by the leukemic blasts such as interleukin (IL) -1b and tissue necrosis factor alpha (TNF-a). 42, 43 Treatment with ATRA induces a decrease in the expression of the TF gene in bone marrow cells. 30 Inflammatory cytokines may generate the production of the fibrinolysis inhibitor plasminogen activator inhibitor type 1 (PAI-1), further contributing to bleeding. 44 Thrombocytosis during ATRA therapy has been reported, and such a finding may be related to increased IL-6 production. 45 Apoptosis induced during cell senescence or by chemotherapy generates procoagulant activity by exposing TF and by cell membrane phosphatidylserine in a variety of cells including vascular smooth muscle, endothelial cells, and leukemic cell lines including NB4 (APL).
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Fibrinolysis
Many patients with APL have elevated levels of urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator, and low levels of plasminogen and a2-antiplasmin, which reflect activation of primary fibrinolysis. [50] [51] [52] Whether the fibrinolysis is primary or secondary has been a matter of some debate. The presence of elevation in D-dimer, the lysis product of stabilized fibrin generated by thrombin formation, suggests that the fibrinolysis is a secondary rather than a primary process. Conversely, there are data suggesting that leukemic promyelocytes from patients with APL strongly express annexin-II, which might be responsible for primary fibrinolysis. 53 Annexin-II is a member of a family of phospholipid-binding membrane proteins that are high-affinity receptors for both plasminogen and tissue plasminogen activator (t-PA) on the cell surface, particularly on monocytes, which results in an 60-fold acceleration of the conversion of plasminogen to plasmin. Annexin-II appears to be more highly expressed on cerebral endothelial cells than endothelial cells from other tissues, which may explain the high incidence of intracerebral hemorrhage. 54 Overexpression of annexin-II appears to be a new mechanism accounting for the bleeding diathesis in APL. 55 Proteolysis A third pathophysiologic process that appears to be active in patients with APL is proteolysis of various proteins by proteases such as elastase and chymotrypsin, present in the granules of myeloid cells and APL cells. Such enzymes may directly degrade fibrinogen and other procoagulant proteins. 56 Elevations in leukocyte elastase and FDPs of elastase reflect activation of a proteolysis. Increased proteolysis of von Willebrand factor is also present in many patients with APL. 57, 58 Increased Angiogenesis Several studies have demonstrated increased blood vessel formation in patients with untreated APL. 59, 60 Increased angiogenesis is mediated by vascular endothelial growth factor (VEGF), and ATRA has been shown to inhibit VEGF production, given that microvessel density (a measure of increased angiogenesis) decreases after ATRA exposure. 59 VEGF stimulates TF production and therefore anti-VEGF strategies beyond ATRA may be useful in resolving the coagulopathy in APL. 61 Impact of ATRA and ATO on the Coagulopathy in APL It has been demonstrated clearly that ATRA induces differentiation of leukemia promyelocytes into mature granulocytes. 62 ATO induces both differentiation at low concentrations and apoptosis at higher concentrations. 63 Both agents ameliorate the coagulopathy rapidly-both clinical bleeding and the laboratory abnormalities associated with untreated APL. ATRA resolves the coagulopathy in a median of 4 days. In patients with relapsed or refractory APL previously treated with ATRA, ATO is associated with resolution of the coagulopathy in a median of 11 days (range, 4 to 28 days). 64 Randomized studies of ATRA for remission induction in APL suggested that the overall complete remission rates and ED rates were modestly, if at all, improved compared with the rates observed with chemotherapy alone. 12, 13 Although the ED rate due to bleeding may have decreased, there appears to be an increase in thrombosis and death due to the retinoic acid syndrome. Although the ED rate remains 10%, roughly 50 to 60% of the EDs are attributable to bleeding (Table 1) . In a retrospective analysis of early hemorrhage during induction in APL among patients treated with or without ATRA, the death rate due to hemorrhage was improved minimally after induction therapy with ATRA and idarubicin compared with idarubicin alone. 65 However, mortality was less with ATRA and idarubicin (7.6 versus 16.2%; p < 0.003). In addition, there was a reduction in the severity of bleeding and blood product consumption.
Several groups have reported that the expression of the markers of activation of both coagulation and fibrinolysis decrease with exposure to ATRA. [28] [29] [30] There is evidence that ATRA reduces the expression of the markers of activation of coagulation more rapidly and more completely than the markers of activation of fibrinolysis. This observation may explain the occurrence of thrombosis seen in some patients treated with ATRA, which creates an imbalance favoring procoagulant forces. In fact, some patients maintain elevated levels of FPA, TAT complexes, F1 þ 2, and D-dimer for more than 30 days after commencing treatment with ATRA. ATRA reduces the expression of such markers more rapidly than chemotherapy. Importantly, ATRA also decreases TF expression in leukemia promyelocytes more profoundly than that seen with chemotherapy. 30 The levels of t-PA increase during treatment with ATRA. In contrast, the levels of PAI-1 appear to be slightly elevated at diagnosis and normalize by day 8 of treatment. However, u-PA remains elevated during treatment. In a study performed in NB4 cells, retinoic acid led to an increase in u-PA activity on the cell surface, which was countered by an increase in PAI-1 and PAI-2. 67 ATRA also reduces the expression of CP in APL. Similarly, the expression of TF is also downregulated by ATRA. Treatment with ATRA also prevents the upregulation of TF by IL-1b and TNF-a. Both ATRA and arsenic trioxide, but not ara-C, downregulate annexin-II expression in leukemia promyelocytes, contributing to a decrease in bleeding. 67, 68 Treatment of the Coagulopathy Associated With APL
CHANGING ROLE OF HEPARIN
The remarkable ability of ATRA to induce differentiation of leukemic promyelocytes and decrease the markers of activation of both coagulation and fibrinolysis has renewed interest in revisiting strategies for the treatment of the coagulopathy, which historically has been the major cause of ED in APL. In the past, heparin commonly was administered to control the coagulopathy in an effort to inhibit thrombin formation when the major process was believed to be DIC. However, a study performed by the Italian cooperative group GI-MEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) in the pre-ATRA era compared the benefits of heparin and antifibrinolytic agents retrospectively and found no benefit for either approach. 69 There has never been a prospective randomized trial of anticoagulant strategies in APL. Given that the use of heparin has been largely empiric, has been based on reports of small numbers of patients, and has been studied prior to the routine introduction of ATRA, heparin generally has been abandoned in contemporary therapeutic strategies that include ATRA during induction.
ANTIFIBRINOLYTIC AGENTS
Small studies have suggested a role for antifibrinolytic therapy. 70, 71 However, both of these reports were published prior to the ATRA era. A large retrospective study and a prospective study have not demonstrated a benefit to the administration of antifibrinolytic agents such as epsilon-aminocaproic acid or tranexamic acid. 69, 71 In two consecutive studies performed by the PETHEMA (Programma de Estudio y Tratamiento de las Hemopatias Malignas) group, the incidence of fatal hemorrhage was compared among patients treated with ATRA and idarubicin with or without prophylactic tranexamic acid. Causes of death at induction did not differ between the two studies. Approximately 50% of deaths occurred during the first week of therapy despite intensive blood product transfusion support. There appeared to be no benefit from the prophylactic use of tranexamic acid. 72 One case report suggested that the combination of ATRA and tranexamic acid contributed to the development of fatal thromboembolism. 73 Activated factor 7 (Novoseven Novo Nordisk; Princeton, NJ) has been reported to be potentially beneficial. 74 
BLOOD PRODUCT SUPPORT
It has been recommended that aggressive blood product transfusions are the mainstay of treatment for the coagulopathy in APL (Table 3) . 72, 75, 76 Thrombocytopenia is usually profound and related to lack of production due to infiltration of the marrow with leukemic promyelocytes as well as to consumption of platelets. It is suggested to maintain the platelet count of at least 30,000 to 50,000/ mL with very aggressive platelet transfusion support even if required several times a day during the initial days of induction until resolution of all evidence of the coagulopathy. Cryoprecipitate is administered to maintain the serum fibrinogen above 100 to 150 mg/dL. Such aggressive blood product support may require transfusions several times each day during the first few days of treatment. Perhaps the most important maneuver to reduce bleeding and decrease the ED rate is to initiate treatment without delay with ATRA when the diagnosis is first suspected based on the clinical picture and review of the morphology of the peripheral blood without waiting for cytogenetic or genetic confirmation. Start treatment of the disease with ATRA and chemotherapy for patients who present with a high white blood cell count APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid.
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